title: [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
abstract: BACKGROUND
  Owing to twenty years of multicentric interdisciplinary cooperation, the COSS group has been able to collect data on a large group of osteosarcoma patients treated by neoadjuvant therapy. This paper reviews results achieved in patients with localized extremity tumors.
  
  
  METHODS
  
  
  
  METHODS
  Registration into a completed neoadjuvant COSS-Study. Histologically confirmed, primary, localized, high-grade, central osteosarcoma of an extremity; age < 40 years; no pretreatment; interval diagnosis to chemotherapy < or = 3 weeks; no severe comorbidity. Chemotherapy: HD-methotrexate +/- doxorubicin +/- cisplatin +/- ifosfamide +/- BCD. Scheduled local therapy: Surgery.
  
  
  RESULTS
  925 evaluable patients from 101 institutions. Median age 15 years, m:f 1.4:1. Primary site: femur 510, tibia 251, humerus 100, fibula 51, other 13. Tumor-size < 1/3 of the involved bone 616, > or = 1/3 304. Definitive surgery in 903/925 cases, 443 limb salvage procedures. Good response (> 90% necrosis) in 469/806 (58.2%) evaluated tumors. Median follow-up for surviving patients: 5.42 years. Actuarial survival after 5 and 10 years: 72.5% (95%-CI 69.3-75.7) and 66.3% (62.5-70.0), relapse-free 62.1% (58.7-65.4) and 59.4% (55.8-63.0). 683/925 alive (601 first remission), 242 deceased (212 tumor progression, 30 other causes). 66.2% (97.3%) of all relapses within 2 (5) years. Prognosis correlates with tumor-size (< vs. > or = 1/3: 69.9% vs. 58.3% at 10 years) and -site (tibia: 74.2%, humerus: 54.5%) and -response (good vs. poor: 78.2% vs. 52.5%) (all p < 0.01). Actuarial 10-year survival by response grading I-VI according to Salzer-Kuntschik 80.9%, 82.8%, 71.1%, 60.7%, 47.7%, 27.3%. COSS-studies with preoperative 4-drug therapy more efficacious than less aggressive protocols. No impact of doxorubicin scheduling (sequential: rapid vs. 48 h-continuous infusion) or cisplatin scheduling (randomized: 5 h vs. 72 h-infusion) on prognosis detected.
  
  
  CONCLUSIONS
  Intensive multiagent chemotherapy and delayed surgery for localized extremity osteosarcoma led to excellent oncologic results in the COSS-studies. Tumor-size, -site, and -response as well as the intensity of upfront chemotherapy correlated with outcome. Giving doxorubicin and cisplatin by continuous infusions did not result in discernible prognostic disadvantages.
authors.affiliation: Universitäts-Kinderklinik, Pädiatrische Hämatologie/Onkologie, Westfälische Wilhelms-Universität Münster.
authors.forename: S
authors.initials: S
authors.lastname: Bielack
authors.forename: B
authors.initials: B
authors.lastname: Kempf-Bielack
authors.forename: D
authors.initials: D
authors.lastname: Schwenzer
authors.forename: T
authors.initials: T
authors.lastname: Birkfellner
authors.forename: G
authors.initials: G
authors.lastname: Delling
authors.forename: V
authors.initials: V
authors.lastname: Ewerbeck
authors.forename: G U
authors.initials: GU
authors.lastname: Exner
authors.forename: N
authors.initials: N
authors.lastname: Fuchs
authors.forename: U
authors.initials: U
authors.lastname: Göbel
authors.forename: N
authors.initials: N
authors.lastname: Graf
authors.forename: U
authors.initials: U
authors.lastname: Heise
authors.forename: K
authors.initials: K
authors.lastname: Helmke
authors.forename: A R
authors.initials: AR
authors.lastname: von Hochstetter
authors.forename: H
authors.initials: H
authors.lastname: Jürgens
authors.forename: R
authors.initials: R
authors.lastname: Maas
authors.forename: N
authors.initials: N
authors.lastname: Münchow
authors.forename: M
authors.initials: M
authors.lastname: Salzer-Kuntschik
authors.forename: J
authors.initials: J
authors.lastname: Treuner
authors.forename: U
authors.initials: U
authors.lastname: Veltmann
authors.forename: M
authors.initials: M
authors.lastname: Werner
authors.forename: W
authors.initials: W
authors.lastname: Winkelmann
authors.forename: A
authors.initials: A
authors.lastname: Zoubek
authors.forename: R
authors.initials: R
authors.lastname: Kotz
mesh_terms: D000293:Adolescent; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000601:surgery; D001133:Bones of Upper Extremity; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007867:Leg Bones; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D012516:Osteosarcoma / Q000188:drug therapy* / Q000601:surgery; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide; D008727:Methotrexate